In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ending the Arms Race: Ten Priorities for Fixing the Commercial Model

The drug industry has seen a massive shift in who influences prescription, payment, and consumption decisions. But corporate capabilities and tactics haven’t kept pace with these new market realities.

Executive Summary

Faced with growing budgets and declining effectiveness of commercial spending, most large companies have embarked on the next wave of significant commercial changes. But most of these efforts don't go far enough to address the rapid and fundamental changes in the stakeholder landscape which have knocked pharma dramatically out of alignment with its stakeholder base. The article describes ten priorities for drug companies to align their organizations with these new realities - including requirements for companies to partner with payors and providers in new ways, and make resource decisions much more selectively to focus on the stakeholders who really matter. Nonetheless, these changes won't have their full effect without a more fundamental rethinking of the industry's value proposition, taking into account not only product value, but the services and the customer experience offered to all stakeholders.

Advertisement

Related Content

Retooling The Sales Force Remains A Work In Progress
J&J Finds More Stakeholders Are Involved In Prescription Decisions And Thus Less Detailing Is Needed - And Eliminates 900 Pharma Sales Positions
Best of the Blog: IN VIVO, March 2009
Best of the Blog: IN VIVO, March 2009
Best of the Blog: IN VIVO February 2009
Best of the Blog: IN VIVO February 2009
Pharma's New Marketing Realities
Pfizer Restructures for a More Flexible Future
No Cure, No Pay: The Future of Drug Marketing?
Winning the Commercial Arms Race

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel